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BACKGROUND AND PURPOSE
Receptor tyrosine kinase inhibitors (RTKIs) targeted at VEGF receptor 2 (VEGFR2) have proved to be attractive approaches to
cancer therapy based on their ability to reduce angiogenesis. Here we have undertaken a quantitative analysis of the
interaction of RTKIs and two VEGF splice variants, VEGF165a and VEGF165b, with VEGFR2 by studying nuclear factor of activated
T-cells (NFAT) reporter gene activity in live HEK-293 cells.
EXPERIMENTAL APPROACH
HEK-293 cells expressing the human VEGFR2 and a firefly luciferase reporter gene regulated by an NFAT response element
were used for quantitative analysis of the effect of RTKIs on VEGF165a- and VEGF165b-stimulated luciferase gene expression.
KEY RESULTS
VEGF165a produced a concentration-dependent activation of the NFAT-luciferase reporter gene in living cells that was inhibited
in a non-competitive fashion by four different RTKIs (cediranib, pazopanib, sorafenib and vandetanib). The potency obtained
for each RTKI from this analysis was similar to those obtained in binding studies using purified VEGFR2 kinase domains.
VEGF165b was a lower-efficacy agonist of the NFAT-luciferase response when compared with VEGF165a. Analysis of the
concentration–response data using the operational model of agonism indicated that both VEGF165 isoforms had similar affinity
for VEGFR2.
CONCLUSIONS AND IMPLICATIONS
Quantitative pharmacological analysis of the interaction of VEGF165 isoforms and RTKIs with VEGFR2 in intact living cells has
provided important insights into the relative affinity and efficacy of VEGF165a and VEGF165b for activation of the calcineurin-
NFAT signalling pathway by this tyrosine kinase receptor.
Abbreviations
NFAT, nuclear factor of activated T-cells; RTKIs, receptor tyrosine kinase inhibitors; VEGFR1, VEGF receptor 1; VEGFR2,
VEGF receptor 2; VEGFR3, VEGF receptor 3
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Introduction
VEGF is an important mediator of cell survival, proliferation
and angiogenesis (Ferrara, 2009; Shibuya, 2011; Musumeci
et al., 2012). It constitutes a family of mammalian homodi-
meric glycoproteins, comprising VEGF-A, VEGF-B, VEGF-C,
VEGF-D and placenta growth factor. VEGF-A is an important
and potent mediator of tumour-induced angiogenesis
(Ferrara, 2004; 2009). VEGF family members bind to three
different VEGF receptors (VEGFR1, VEGFR2 and VEGFR3)
with differing selectivity profiles (Ferrara, 2009; Shibuya,
2011). VEGFR2 is the major regulator of VEGF-driven
responses in vascular endothelial cells including permeabil-
ity, proliferation, invasion and migration. It is also considered
to be a crucial mediator of angiogenesis (Ferrara, 2009;
Shibuya, 2011). Its signalling pathways are relatively well
understood with tyrosine residues Y1175 and Y1214 in the
human VEGFR2 being the main auto-phosphorylation sites
activated by VEGF binding and tyrosine kinase activation.
This creates binding sites for key intracellular signalling pro-
teins such as Grb2, PLCγ and Shc1 (Matsumoto and
Mugishima, 2006; Rososki, 2008; Koch et al., 2011).
The transmembrane glycoprotein neuropilin 1 forms a
complex with VEGFR2 and acts as a co-receptor to enhance
VEGF-A binding, mediate focal adhesion kinase phosphoryla-
tion and increase cell migration (Herzog et al., 2011). It has
also been shown to promote VEGFR2 internalization and
endosomal trafficking, leading to the regulation of ERK sig-
nalling and cell proliferation (Lanahan et al., 2013). Neuro-
pilin 1 is engaged by specific VEGF isoforms and has recently
been the target of drug discovery efforts to design low MW
inhibitors of neuropilin 1 (Djordjevic and Driscoll, 2013).
Multiple isoforms of VEGF-A, ranging from 121 to 206 amino
acids, can be generated by alternative exon splicing that differ
in their ability to bind heparin (affecting bioavailability) or
neuropilin 1 and they appear to play distinctive roles in
angiogenesis (Woolard et al., 2004; 2009; Ferrara, 2009). For
example, alternative splicing in exon 8 of the VEGF gene can
generate VEGFxxxa and VEGFxxxb (where xxx is the amino acid
length) isoforms that have been reported to have pro-
angiogenic and anti-angiogenic activities respectively
(Woolard et al., 2004; 2009). In keeping with this, VEGF165b
has been reported to be a weak partial agonist at VEGFR2,
able to bind weakly to heparin and does not interact with
neuropilin-1 (Cebe Suarez et al., 2006; Catena et al., 2010).
Receptor tyrosine kinases inhibitors (RTKIs) targeted at
VEGFR2 have proved to be attractive approaches to cancer
therapy based on their ability to reduce angiogenesis and/or
lymph-angiogenesis (Musumeci et al., 2012). There are three
known classes of RKTIs. Class I RTKIs, such as cediranib,
vandetanib and pazopanib, are able to bind to the active
conformation of the receptor and compete for the intracellu-
lar ATP-binding site within the catalytic domain of VEGFR2
(Gotink and Verheul, 2010; Davis et al., 2011; Blasi et al.,
2012). Class II RTKIs, such as sorafenib, bind to the non-
active conformation of the receptor at the hydrophobic
pocket of the activation loop and inhibit kinase activity by
indirectly preventing the binding of ATP (Gotink and
Verheul, 2010; Davis et al., 2011). Finally, class III RTKIs such
as neratinib, covalently bind to cysteine residues within the
intracellular ATP-binding region of the receptor (Gotink and
Verheul, 2010; Davis et al., 2011). Most of these small mol-
ecule RTKIs interact with multiple members of the PK family
(Davis et al., 2011). For example, binding studies with puri-
fied kinase domains have shown that vandetanib is a more
potent inhibitor of Abl1 (16 nM), EGFR (9.5 nM), MEK5
(49 nM) than VEGFR2 (820 nM) (Davis et al., 2011).
Quantitative evaluation of the interactions of RTKIs with
VEGFR2 in living cells has, however, been largely lacking.
This is important as, by definition, all RTKIs need to access
the intracellular regions of VEGFR2 in order to elicit their
pharmacological action. It is therefore vital to understand
how the different RTKIs affect VEGF165a- and VEGF165b-
mediated signalling in intact cells. The aim of the present
Tables of Links
TARGETS
Catalytic receptorsa
EGFR, EGF receptor
VEGFR1, VEGF receptor 1
VEGFR2, VEGF receptor 2
VEGFR3, VEGF receptor 3
Enzymesb
Akt
Abl1
MEK5
PKC
PLCγ
LIGANDS
Cediranib
IP3, inositol-1,4,5-trisphosphate
Pazopanib
Sorafenib
Vandetanib
VEGF-A
VEGF-B
VEGF-C
VEGF-D
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
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study was to undertake a quantitative pharmacological analy-
sis of the effect of VEGF165 isoforms and RTKIs on VEGFR2-
mediated signalling in living cells. An important signalling
pathway for VEGFR2 is the calcineurin-nuclear factor of acti-
vated T-cells (NFAT) system that, following activation by
VEGF, leads to nuclear translocation of the NFAT transcrip-
tion factor and expression of pro-angiogenic and pro-
inflammatory genes (Suehiro et al., 2014; Yang et al., 2014).
Reporter gene systems have been used extensively to study
GPCRs and provide an alternative to biochemical assays for
following signal transduction pathways from receptors at the
cell surface to nuclear gene transcription in living cells (Hill
et al., 2001). Here we have used an NFAT-luciferase reporter
gene to investigate the impact of four representative RTKIs on
VEGF165a- and VEGF165b-stimulated NFAT-luciferase activity
in HEK-293 cells expressing human VEGFR2.
Methods
Cell lines
HEK-293 cells expressing the human VEGFR2 and an NFAT
reporter gene were provided by Promega Corporation. The
NFAT reporter gene contained an NFAT response element
linked via a minimal promoter to the firefly luciferase gene
luc2P containing a human sequence enriched in proline (P),
glutamic acid (E), serine (S) and threonine (T) protein desta-
bilization sequence (Voon et al., 2005). VEGFR2 NFAT cells
were maintained in DMEM media supplemented with 10%
FCS and 0.5% G418 in a humidified 5% CO2/95% air atmos-
phere at 37°C.
Measurement of VEGFR2-stimulated
NFAT-reporter gene activity in HEK-293 cells
VEGFR2 NFAT cells were seeded in a T75 flask at 5 × 106 cells
per flask using DMEM +10%FCS and incubated at 37°C in a
5% CO2/95% air atmosphere for 3 days until the cells were
100% confluent. On the fourth day, cells were washed with
PBS and detached using 3 mL Versene® (ETDA 0.02% in PBS).
Once cells had detached, 6 mL of DMEM +0.1%BSA was
added and the cells were counted using a haemocytometer.
Cells were centrifuged at 200× g for 5 min, resuspended in
DMEM +0.1%BSA and seeded at a density of 4 × 104 cells per
well in 80 μL DMEM +0.1%BSA in white-sided, clear flat-
bottomed 96-well plates (Greiner, Stonehouse, UK), which
had been coated with 0.01 mg·mL−1 poly-D-lysine in PBS for
30 min and washed with DMEM. Cells were then incubated
for 1 h in a humidified 5% CO2/95% air atmosphere at 37°C.
RTKIs or vehicle control were added in 10 μL DMEM
+0.1%BSA for 1 h prior to addition of VEGF165a or VEGF165b in
10 μL DMEM +0.1%BSA and the incubation was continued
for a further 5 h (in a humidified 5% CO2/95% air atmosphere
at 37°C). After the 5 h incubation, 100 μL ONE-Glo Luciferase
Assay reagent was added to each well and luminescence was
measured according to the manufacturer’s instructions on a
Topcount platereader (Perkin Elmer, Llantrisant, UK).
Data analysis
All data were fitted using non-linear regression in Prism 6
(GraphPad Software, San Diego, CA, USA). VEGF165a and
VEGF165b concentration–response curves were fitted to the
following equation:
Response max=
× [ ]
[ ] +
E A
A EC50
(1)
Where Emax is the maximal response, and the EC50 is the molar
concentration of agonist required to generate 50% of the Emax.
When investigating the effect of different concentrations of
RTKI on concentration–response curves for VEGF165a, the
data were also fitted to Equation (1) with parameters for
either EC50 of Emax shared between all curves. A comparison of
the extra sum of squares that resulted from the analysis with
separate EC50 or Emax values (over that with one of the param-
eters shared) using the F-test (Prism 6) then allowed for sta-
tistical analysis of the difference between EC50 or Emax values.
Inhibition curves obtained with RTKIs in the presence of
a fixed concentration of VEGF165a or VEGF165b were fitted to
the following equation:
% Response to VEGF =
×
[ ] +
100 50
50
IC
A IC
(2)
Where [A] is the concentration of RTKI and the IC50 is the
molar concentration of ligand required to inhibit 50% of the
response to VEGF.
Partial agonist concentration–response curves to VEGF165b
were also fitted to the operational model of Black and Leff
(1983) using the following equation:
Response max=
× × [ ]
+ [ ]( ) + × [ ]
E A
K A A
n n
A
n n n
τ
τ
(3)
Where Emax is the maximal response of the system, [A] is the
concentration of VEGF165b, n is the slope parameter, KA is
the dissociation constant of the agonist VEGF165b and τ is the
transducer constant, which is a practical measure of efficacy.
τ is the inverse of the fraction of receptors that must be
occupied by agonist to obtain the half-maximal response.
Emax was determined by simultaneously fitting Equation (1) to
the concentration–response data for VEGF165a that were
obtained in the same experiments as those for VEGF165b. Emax
was shared between the two simultaneous fits.
Equation (3) was also used to simultaneously fit
concentration–response curves to VEGF165a in the presence
and absence of increasing concentrations of a define RTKI. In
this case, Emax, n and KA (which in this case is the dissociation
constant of VEGF165a) were shared between the simultaneous
fits.
All data are presented as mean ± SEM. The n in the text
refers to the number of separate experiments. Statistical sig-
nificance was determined by Student’s unpaired t-test or by
one or two-way ANOVA with Dunnett’s post hoc analysis and P
< 0.05 was considered statistically significant.
Materials
VEGF165a and VEGF165b were obtained from R&D systems
(Abingdon, UK). Vandetanib, pazopanib, cediranib and
sorafenib were supplied by Sequoia Research Products (Pang-
bourne, UK). The ONE-Glo™ Luciferase Assay System was
obtained from Promega Corporation (Madison, WI, USA).
Versene was obtained from Lonza (Basal, Switzerland). G418
was purchased from Life Technologies (Paisley, UK). All other
chemicals and reagents were purchased from Sigma-Aldrich
(Gillingham, UK).
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Results
VEGF165a-stimulated NFAT-luciferase
production in intact cells
Incubation with VEGF165a produced a concentration-
dependent (pEC50 9.66 ± 0.05, n = 10) increase in NFAT-
mediated luciferase production in HEK-293 cells expressing
VEGFR2 that was 8.30 ± 0.85-fold (n = 10) over basal levels
(Table 1; Figure 1A and B). The response to 1 nM VEGF165a
was inhibited by the RTKI cediranib in intact HEK-293 cells in
a concentration-dependent manner (Figure 1C; Table 2). The
pIC50 obtained for cediranib (9.13; Figure 2A, Table 2) was in
close agreement with that reported from binding studies with
the purified VEGFR2 kinase domain (Davis et al., 2011). It was
also noticeable that there was no marked inhibition by
cediranib below basal levels at the highest concentration used
(Figures 1C and 2A), suggesting that the ability of this RTKI to
inhibit other tyrosine kinases (e.g. PDGFR-A, PDGFR-B and
EGFR, Davis et al., 2011) did not significantly impact on the
response observed. This was confirmed when the effect of
cediranib was evaluated for its ability to inhibit basal NFAT-
luciferase production (Figure 1D). A significant inhibition
Table 1
Concentration–response parameters for VEGF165a- and VEGF165b-stimulated NFAT-luciferase responses
−Log EC50 Emax (% VEGF165a max) n
VEGF165a 9.66 ± 0.05 100 10
VEGF165b 9.21 ± 0.08 62.1 ± 1.2 5
Values are mean ± SEM of n separate experiments. Each individual experiment was performed in quadruplicate.
Figure 1
The effect VEGF165a on NFAT-mediated gene transcription in VEGFR2 NFAT cells. VEGFR2 NFAT cells were treated with VEGF165a (A and B) or
cediranib +1 nM VEGF165a (C). Data are mean ± SEM from quadruplicate determinations in a single representative experiment that was repeated
on five separate occasions (A and C). Normalized data from five repeat experiments expressed as a percentage of the response to 10 nM VEGF165a
in each experiment (B). Effect of cediranib on basal NFAT-luciferase activity (D). Data are mean ± SEM from quadruplicate determinations in a
single representative experiment that was repeated on five separate occasions. The histogram in (A) and (C) show the control response to 1 nM
VEGF165a (A and C) and that to VEGF165a in the presence of the vehicle (containing DMSO) for the highest concentration of cediranib used in the
competition experiment shown in (C).
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(P < 0.05; one way ANOVA) of the small basal NFAT-luciferase
response was only observed at concentrations of cediranib
above 10 nM (Figure 1D). Analysis of all five repeat experi-
ments indicated that a significant inhibition of basal signal-
ling was only obtained at the two highest concentrations
used (P < 0.05; one way ANOVA; n = 5).
Inhibition of 1 nM VEGF165a-stimulated NFAT-luciferase
activity was also obtained with a second-class I RTKI (pazo-
panib, which has a different inhibitor selectivity profile com-
pared with cediranib, e.g. FGFR1-3, PDGFRA/B, VEGFR1 and
EGF; Davis et al., 2011) and with sorafenib and vandetanib
(Figure 2, Table 2). All RTKIs tested produced pIC50 values,
which were in agreement with those reported previously in
binding studies on purified VEGFR2 kinase domains
(Table 2). As with cediranib, there was no marked inhibition
below basal responses (Figure 2B) with pazopanib (which is
Table 2
The effect of selected RTKIs on VEGF-stimulated firefly luciferase production in VEGFR2 NFAT cells
Inhibition of 1 nM
VEGF165a pIC50 n
Inhibition of 3 nM
VEGF165b pIC50 n
Reported binding pKD for
purified kinase domain*
Cediranib 9.13 ± 0.01 5 9.38 ± 0.07 5 8.96
Pazopanib 8.25 ± 0.03 5 8.29 ± 0.10 8 7.85
Sorafenib 8.01 ± 0.06 5 7.96 ± 0.04 5 7.23
Vandetanib 6.72 ± 0.03 5 7.00 ± 0.04 6 6.08
VEGFR2 NFAT cells were treated with each RTKI and either 1 nM VEGF165a or 3 nM VEGF165b. Data are mean ± SEM of n separate experiments.
Each individual experiment was performed in quadruplicate. Individual fitted values for pIC50 values were obtained in each individual
experiment and then analysed to provide mean ± SEM data provided here.
*Values taken from Davis et al., 2011.
Figure 2
The effect of selected RTKIs on NFAT gene transcription stimulated by 1 nM VEGF165a. VEGFR2 NFAT cells were treated with (A) cediranib, (B)
pazopanib, (C) vandetanib or (D) sorafenib. Data are mean ± SEM of five separate experiments. Data are expressed as a percentage of the response
to 1 nM VEGF165a in the absence of RTKIs. Each individual experiment was performed in quadruplicate.
BJPVEGFR2-stimulated gene transcription
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also a potent PDGFR inhibitor, Davis et al., 2011). In contrast,
both sorafenib (−25.0 ± 2.6%, n = 5) and vandetanib (−23.0 ±
3.7%, n = 5) produced a small significant inhibition (P < 0.05,
paired t-test) below basal levels, which may reflect some
interference with other tyrosine kinases at the higher
concentrations required to inhibit VEGFR2 with these
inhibitors.
VEGF binding to VEGFR2 requires Ig-like domains D2 and
D3 in the extracellular portion of the receptor (Dosch and
Ballmer-Hofer, 2010; Leppänen et al., 2010). In contrast, the
kinase domain, which is the target for RTKIs lies within the
intracellular portion of the receptor. As a consequence,
the interaction between VEGF and RTKI in intact cells
should show classical non-competitive interactions when
concentration–response curves to VEGF165a are analysed in
the presence of increasing concentrations of RTKIs. These
data for VEGF-stimulated NFAT-luciferase production are
shown in Figure 3 and Table 3. All four inhibitors produced a
significant (P < 0.05) concentration-dependent reduction in
the maximal response to VEGF165a (Table 3). Analysis of all
the individual experiments indicated that there was a small,
but significant change (P < 0.05) in EC50 at the highest con-
centrations of RTKIs used (Table 3). However, global analysis
of the combined data presented in Figure 3 indicated that
there was only a significant difference in the EC50 values for
cediranib (P < 0.05). In contrast, there was a significant
decrease in Emax with all four RTKIs (P < 0.001; extra sum of
squares F-test; Figure 3).
Pharmacological characteristics of the splice
variant, VEGF165b, in HEK-293 cells
In the present study, VEGF165b produced a robust NFAT-
luciferase response in HEK-293 cells expressing human
VEGFR2 that accounted for 62.1% (Table 1, Figure 4) of the
maximum response obtained with VEGF165a in the same
experiments. The EC50 values were, however, very similar
(Table 1, Figure 4A). Analysis of the concentration–response
curves using the operational model of Black and Leff (1983)
for partial agonists indicated that the log KA for VEGF165b was
−8.83 ± 0.13 (n = 5) and the transducer constant τ was 1.65 ±
0.23 (n = 5). τ is a measure of agonist efficacy and represents
the inverse of the fraction of receptors (60.1%) that must be
occupied by agonist to obtain the half-maximal response
(Black and Leff, 1983). The response to 3 nM VEGF165b was
sensitive to inhibition by RTKIs with similar potencies to
those obtained when VEGF165a was used as agonist (Figure 4B;
Table 2).
Figure 3
The effect of RTKIs on VEGF165a concentration–response curves. VEGFR2 NFAT cells were treated with (A) pazopanib, (B) vandetanib, (C) cediranib
or (D) sorafenib for 1 h prior to the addition of increasing concentrations of VEGF165a. Data are mean ± SEM of five (A and B), six (C) or seven
(D) replicate experiments. Each individual experiment was performed in quadruplicate. Global analysis of the combined data presented for each
RTKI (A–D; extra sum of squares F-test) indicated that there was only a significant difference in the EC50 values for cetiranib (P < 0.05). In contrast,
there was a significant decrease in Emax with all four RTKIs (P < 0001; Figure 3; extra sum of squares F-test).
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Discussion
VEGF receptors have been shown to activate several intracel-
lular signalling pathways including PKC, PLCγ, MAPK and
calcium-calcineurin (Suehiro et al., 2014). Calcineurin signal-
ling activates NFAT transcription factors leading to the stimu-
lation of gene transcription (Hill et al., 2001; Suehiro et al.,
2014; Yang et al., 2014). Stimulation of PLCγ increases levels
of inositol-1,4,5-trisphosphate (IP3) and diacyglycerol. IP3
then stimulates the release of intracellular calcium while dia-
cylglycerol activates PKC. Increased intracellular calcium
concentration stimulates calcineurin leading to the dephos-
phorylation of cytoplasmic NFAT transcription factors allow-
ing them to translocate to the nucleus. In parallel, PKC
activation results in the production of the AP-1 immediate
early genes c-fos and c-jun. Once in the nucleus, NFAT binds
with c-fos and c-jun to form a transcriptional complex
capable of synergistically activating both the NFAT and the
AP-1 response elements to stimulate gene expression (Masuda
et al., 1998; Macian et al., 2000; Hill et al., 2001). In endothe-
lial cells, VEGF treatment leads to NFAT nuclear localization
and the expression of pro-angiogenic and pro-inflammatory
genes (Suehiro et al., 2014; Yang et al., 2014). Furthermore,
the calcineurin-NFAT pathway appears to be an important
route for VEGF-mediated signalling (Suehiro et al., 2014; Yang
et al., 2014). Here we have used a reporter gene containing
the NFAT promoter coupled to the expression of firefly lucif-
erase (Hill et al., 2001; Voon et al., 2005) to investigate in
living cells the pharmacological characteristics of VEGF165a-
and VEGF165b-induced gene expression in HEK-293 cell trans-
fected with human VEGFR2.
Both VEGF165a and VEGF165b were able to produce a robust
and potent stimulation of NFAT-mediated luciferase gene
expression after 5 h of incubation. Both isoforms had very
similar EC50 values that were in the nanomolar range
(Table 1). This is in keeping with previous reports that
VEGF165b has a lower efficacy than VEGF165a for VEGFR2-
mediated responses (Woolard et al., 2004; Cebe Suarez et al.,
2006; Kawamura et al., 2008; Catena et al., 2010). The alter-
natively spliced variant VEGF165b was a partial agonist of
NFAT-luciferase production eliciting a maximal response that
was only 62% of that achieved by VEGF165a. Analysis of the
VEGF165b concentration–response data using the operational
model of Black and Leff (1983) provides a means by which
both the dissociation binding constant (KA) and the efficacy
(in terms of the τ constant) of VEGF165b can be estimated. This
Table 3
Effect of RTKIs on VEGF165a concentration–response parameters
Vandetanib Pazopanib Cediranib Sorafenib
nM pEC50 % Emax nM pEC50 % Emax nM pEC50 % Emax nM pEC50 % Emax
0 9.90 ± 0.14 100.0 0 9.66 ± 0.11 100.0 0 9.68 ± 0.09 100.0 0 9.72 ± 0.06 100.0
30 9.77 ± 0.10 81.0 ± 4.1 1 9.50 ± 0.09 85.2 ± 7.0 0.3 9.40 ± 0.10 64.8 ± 10.4* 3 9.50 ± 0.05 70.1 ± 6.9*
100 9.75 ± 0.12 58.5 ± 5.7* 3 9.43 ± 0.13 71.4 ± 5.2* 1 9.28 ± 0.12 31.1 ± 6.6* 10 9.33 ± 0.06* 52.9 ± 5.1*
300 9.41 ± 0.14* 29.5 ± 7.9* 10 9.14 ± 0.16* 32.8 ± 2.0* 3 9.13 ± 0.18* 8.8 ± 1.9* 30 9.00 ± 0.13* 18.9 ± 8.9*
pEC50 and Emax values for VEGF165a obtained in the presence of increasing concentrations of four RTKIs.
*P < 0.05 compared with corresponding control in the absence of RTKI (one-way ANOVA). Values are mean ± SEM from six (cediranib), five
(pazopanib), seven (sorafenib) and five (vandetanib) separate experiments.
Figure 4
Characterization of the effect of VEGF165b on NFAT-luciferase repsonses. (A) A comparison of VEGF165a and VEGF165b concentration–response
curves. (B) Inhibition of VEGF165b-stimulated NFAT-luciferase responses by cediranib. In (B), the concentration of VEGF165b was 3 nM. Data are
mean ± SEM of five separate experiments. Four replicates were made for each condition in each individual experiment.
BJPVEGFR2-stimulated gene transcription
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produced an estimate for pKA of VEGF165b at VEGFR2 (8.83)
and a value of 1.65 for the efficacy parameter τ (indicating
that 60.1% of receptors need to be occupied by VEGF165b in
order to achieve 50% of the maximal cellular response). The
similarity of EC50 values for the two VEGF isoforms, however,
suggests that the relatively large response to VEGF165b com-
pared with that seen in other studies (Cebe Suarez et al., 2006;
Kawamura et al., 2008; Catena et al., 2010) is not a conse-
quence of a large amplification of the signalling pathways to
NFAT-mediated gene expression in these cells. Furthermore,
previous work has suggested that VEGF165a and VEGF165b have
the same binding affinities for VEGFR2 (Woolard et al., 2004;
Cebe Suarez et al., 2006).
Interestingly, previous work has indicated that the extent
to which VEGF165b can elicit responses may depend on the
cellular context and the signalling cascade measured. Thus,
while VEGF165b was a very weak agonist of MAPK and Akt
phosphorylation in VEGFR2 transfected CHO cells, it was
able to stimulate a robust MAPK and Akt phosphorylation in
human microvascular endothelial cells (Woolard et al., 2004).
Furthermore, signalling pathway differences in the relative
efficacy of VEGF-A isoforms have been observed for the acti-
vation of VEGFR2-mediated responses (ERK1/2, p38 MAPK,
Akt) in HUVECs by VEGF165a and VEGF121a (Fearnley et al.,
2014). Previous studies, however, have largely been based on
Western blot analysis, and it is clear that the NFAT-luciferase
system reported here provides a powerful system for the
quantitative evaluation of concentration–response relation-
ships for drugs interacting with human VEGFR2 in living
cells.
Four representative RTKIs (cediranib, pazopanib, vande-
tanib and sorafenib) were able to inhibit both VEGF165a- and
VEGF165b-mediated NFAT-luciferase expression with similar
potency, and yielded IC50 values that were similar to the KD
values reported from binding studies with purified VEGFR2
kinase domains (Davis et al., 2011). This similarity suggests
that all four compounds readily cross the cell membrane in
intact living cells. The target for VEGF binding within
VEGFR2 is to domains D2 and D3 of the extracellular portion
of the receptor (Dosch and Ballmer-Hofer, 2010; Leppänen
et al., 2010). In contrast, RTKIs interact in various ways
(depending on RTKI class) with the intracellular kinase
domain of the receptor. As a consequence, the interaction
between VEGF and RTKI in intact cells would be expected to
show classical non-competitive interactions and lead to a
marked change in the maximum response to VEGF165a with
little impact on the EC50 value for the agonist. This is what
was observed in the present study (Figure 3). All four RTKIs
produced a marked reduction in the Emax values for VEGF165a
with only a small change in the pEC50 value. At the highest
concentrations of RTKIs used, the pEC50 was generally
between 9.00 and 9.14, which provides an indication of the
PKA for VEGF165a. Global analysis of the combined data
shown in Figure 3 for each inhibitor (using the extra sum
of squares F-test) indicated that it was only cediranib that
had a significant difference in EC50 between the four sets of
VEGF165a concentration–responses curves.
The non-competitive nature of the inhibition produced
by RTKIs via the intracellular kinase domain, however, pro-
vided an opportunity to estimate the binding affinity of
VEGF165a by utilizing the operational model of Black and Leff
(1983). In this model, the transducer ratio tau (τ) is a measure
of efficacy and reflects the ratio (total receptor number)/KE
where KE describes the hyperbolic relationship in the system
between the response and the concentration of agonist-
receptor complexes. Receptor alkylation experiments have
been used previously to reduce the number of binding sites as
a way to obtain concentration–response relationships with
different τ values, but with common values for KE, Emax and
KA. Use of an RTKI targeted against VEGFR2 kinase activity is
also a way of reducing τ values without changing the
maximal capacity of the NFAT reporter gene system in the
cells. In this case, the inhibition of the VEGFR2 kinase activ-
ity will interfere with signal transduction at the level of the
receptor. This will effectively alter the KE value and increase
the concentration of agonist–receptor complexes needed to
produce a function response. However, this analysis assumes
that the RTKI has no allosteric effect on the binding affinity
of VEGF165a. Thus, increasing concentrations of RTKIs should
decrease the apparent efficacy of VEGF165a in this cellular
system and reduce the transducer constant τ. All other param-
eters in terms of KA, Emax and should, however, remain
unchanged.
If the concentration–response curves obtained with a
given RTKI presented in Figure 3 are simultaneously analysed
on this basis (with these assumptions), the following esti-
mates of the pKA value for VEGF165a are obtained: 8.9, 8.9, 9.4
and 9.0 (for the data sets obtained with cediranib, sorafenib,
vandetanib and pazopanib respectively). The mean value
obtained from this analysis for VEGF165a (8.9) is almost iden-
tical to that obtained for the partial agonist VEGF165b (8.8) in
keeping with previous reports that their affinities are identical
(Woolard et al., 2004; Cebe Suarez et al., 2006). Interestingly,
vandetanib produced a higher estimate for the pKA of
VEGF165a than that obtained with the other RTKIs. This
suggests that the nature of the interaction of vandetanib with
VEGFR2 has produced an allosteric conformational change in
the ligand binding site for VEGF165a and altered its affinity for
VEGF165a.
It should be noted that all four RTKIs produced a small
inhibition of the responses to VEGF165a and VEGF165b below
basal levels (Figure 2; Figure 4B). A similar effect has been
seen with other RTKs (Forsell et al., 2012) and has been
ascribed to constitutive activity of the receptor. However, in
the present study, the effect is likely to be due to inhibition of
other tyrosine kinases within this cell line. The effect of
cediranib on basal NFAT signalling seen in Figure 1D is
consistent with this, particularly at the higher concentration
used. Thus, the potency of cediranib for inhibition of
VEGF-stimulated NFAT signalling and basal NFAT signalling,
respectively, are quite different (Figure 1C and D). Thus,
although the major effects of RTKIs reported here are conse-
quences of an interaction with VEGFR2, it must be remem-
bered that interference with other tyrosine kinase signalling
cascades is possible at higher concentrations of these
inhibitors.
In summary, the present study has shown that the
VEGFR2 NFAT-luciferase reporter gene system provides a
robust way to investigate, in a quantitative manner, the inter-
action of drugs (both agonists and RTKIs) with VEGFR2 in an
intact cellular environment. Quantitative pharmacological
analysis of the interaction of these drugs with VEGFR2 in
BJP J J Carter et al.
3148 British Journal of Pharmacology (2015) 172 3141–3150
living cells has provided important insights into the relative
affinity and efficacy of VEGF165a and VEGF165b for activation
of the calcineurin–NFAT signalling pathway by this tyrosine
kinase receptor. This opens the way for similar quantitative
approaches to be used to evaluate affinity and efficacy meas-
ures for different VEGF isoforms in mediating responses via
other signalling cascades. This should shed light on the
potential for VEGFR2 agonists to bias signalling to particular
intracellular pathways.
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